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Abstract
Background: There is a significant requirement for the development and acquisition of reagents
that will facilitate effective diagnosis, treatment, and prevention of Lassa fever. In this regard,
detection of early markers of Lassa virus (LASV) infection may improve diagnosis and ultimately
successful treatment with antivirals. Characterization of LASV GP1 ectodomain shedding is an
important step toward developing sensitive diagnostics to detect circulating levels of this viral
glycoprotein in infected patient sera.
Results: Secretion of GP1 from mammalian cells expressing a native LASV GPC gene was not
mediated by proteolytic cleavage, as determined by treatment with a panel of matrix
metalloprotease (MMP) inhibitors. The shedding of GP1 was also not the result of over-expression
of GPC under the control of a strong intron-A containing CMV promoter, as the soluble
component could be immunoprecipitated from supernatants of cells expressing low levels of GPC
under the control of an intronless promoter. Cells transfected with GPC retained surface
membrane-associated expression of GP1 as determined by immunofluorescence assay, in addition
to secreting the glycoprotein.
Secreted GP1 derived from GPC expression has a higher content of high mannose N-linked
glycosylation than sGP1 expressed independently from the GP2 portion of the protein. Neither
GP1 isoform contains sialylated N-glycans, O-linked carbohydrate chains, or galactose-β(1-4)-N-
acetylglucosamine commonly present in complex and hybrid N-glycan structures.
Conclusion: These results demonstrate the non-proteolytic secretory nature of GP1 shedding
during expression of the arenaviral glycoprotein complex. This phenomenon parallels shedding of
a secretory glycoprotein component in filovirus replication. The glycosylation pattern of soluble
GP1 resulting from expression of GPC was different from that of a soluble GP1 construct (sGP1-
RRAA-FLAG), highlighting the intricately orchestrated post translational processing of the LASV
glycoprotein complex.
Background
Lassa virus, a member of the Arenaviridae family, is the eti-
ologic agent of Lassa fever, which is an acute and often
fatal illness endemic to West Africa. There are an esti-
mated 300,000 - 500,000 cases of Lassa fever each year [1-
3], with a mortality rate of 15%-20% for hospitalized
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patients and as high as 50% during epidemics [4,5]. Pres-
ently, there is no licensed vaccine or immunotherapy
available for preventing or treating this disease. Although
the antiviral drug ribavirin is beneficial, it must be admin-
istered at an early stage of infection to successfully alter
disease outcome, thereby limiting its utility [6]. Further-
more, there is no commercially available Lassa fever diag-
nostic assay, thus preventing early detection and rapid
implementation of existing treatment regimens (e.g. riba-
virin administration). The lack of adequate countermeas-
ures and means of detection, coupled with the severity of
disease, contributed to the classification of LASV as a
National Institutes of Allergy and Infectious Diseases
(NIAID) Category A pathogen and biosafety level-4 (BSL-
4) agent.
The LASV genome is comprised of two ambisense, single-
stranded RNA molecules, designated small (S) and large
(L) [7]. Two genes on the S segment encode the nucleo-
protein (NP) and two envelope glycoproteins (GP1 and
GP2); whereas, the L segment encodes the viral polymer-
ase (L protein) and RING finger Z matrix protein. GP1 and
GP2 subunits result from post-translational cleavage of a
precursor glycoprotein (GPC) by the protease SKI-1/S1P
[8]. GP1 serves a putative role in receptor binding, while
GP2 has the structural features characteristic of class I viral
fusion proteins [9].
Recently we reported that expression of wild type LASV
GPC in mammalian cells results in the generation of sig-
nificant levels of soluble GP1 in the supernatants of trans-
fected cells, that is not associated with GP2 [11]. GP1
ectodomain shedding from cells expressing wild type
LASV GPC establishes potential new correlates of disease
progression and highlights additional opportunities for
development of diagnostics targeting the early stages of
Lassa fever. In these studies the mechanism of LASV GP1
ectodomain shedding was further elucidated and its char-
acteristics compared and contrasted to a similar phenom-
enon in filoviruses, as previously reported for Ebola virus
(EBOV) [12].
Results
Matrix metalloprotease inhibitors do not affect the 
secretion of GP1 from LASV GPC expressing cells
The effects of a diverse set of MMP inhibitors on the secre-
tion of a soluble GP1 component from high level expres-
sion of LASV GPC in human cells were investigated. None
of the inhibitors employed in these studies resulted in sta-
tistically significant reduction in the levels of secreted GP1
from HEK-293T/17 cells expressing LASV GPC (Figure 1A,
D, lanes 1 - 12), when compared to untreated controls
(Figure 1A, D, lanes 13, 14) [p > 0.05, N = 3]. Relative lev-
els of secreted GP1 for each condition were normalized on
GPC expression in the presence of 1% DMSO, the solvent
for the majority of inhibitors employed in these studies
(Figure 1A, D, lane 13). Inhibitors were added to cells 12
hours after transfection, the earliest time that GP1 could
be detected in cell culture supernatants, thereby marking
the onset of glycoprotein secretion (Figure 1B, lane 17).
The effects of inhibitors on cellular metabolism were
measured by reduction of tetrazolium salt (MTT) and
quantitated by A570 absorbance in 96 well plates mimick-
ing the conditions used in the 6 well plate format. With
the exception of MMP-2 inhibitor 1 (Figure 1E, lane 8) [p
< 0.001, N = 3] cellular metabolism was not adversely
affected by MMP inhibitors and conditions used in these
assays. Despite significantly lowered MTT reduction in
cells expressing GPC and treated with MMP-2 inhibitor I,
the levels of secreted GP1 were equivalent to those in
untreated and control treated cells (Figure 1D, lane 8).
Expression of GPC in HEK-293T/17 cells did not adversely
affect cellular metabolism, as MTT reduction levels were
nearly identical to those obtained with pcDNA vector
alone (Figure 1E, lanes 13 - 16).
Secretory pathway inhibitors abrogate secretion of GP1 
from LASV GPC expressing cells
The effects of secretory pathway inhibitors brefeldin-A
(BFA) and monensin on expression of GPC and secretion
of soluble GP1 were investigated. At 12 hours post trans-
fection intracellular levels of GPC and processed GP1
were approximately 70% of those at 36 hours (Figure 2A,
lanes 1 and 2), although secreted GP1 was barely detecta-
ble in cell culture supernatants (Figure 2B, lanes 1 versus
2). Addition of BFA at the onset of transfection with GPC
resulted in an average of 80% reduction in intracellular
levels of GP1, with undetectable secreted glycoprotein at
36 hours (Figure 2A, B, lane 3). Addition of BFA at 12
hours post transfection resulted in higher levels of accu-
mulated intracellular GP1 than when the inhibitor was
added at the onset, but still resulted in undetectable glyc-
oprotein secreted into the culture supernatant. Treatment
of cell with monensin resulted in overall higher levels of
accumulated intracellular protein than in BFA-treated
reactions, both when it was added at the onset or 12 hours
post transfection (Figure 2A, lanes 7 and 8). Secretion of
GP1 was abrogated when monensin was added at the
onset of transfection, although very low levels of the glyc-
oprotein could be detected in supernatants of cells treated
with the inhibitor at 12 hours (Figure 2B, lane 8). Overall,
treatment with BFA resulted in lowered intracellular GPC
expression than with monensin, irrespective of the time of
inhibitor addition to culture medium, as assessed by lev-
els of detectable GP1 protein at 36 hours. Inhibition with
BFA targets glycoprotein transport within the ER - cis Golgi
environment, whereas monensin targets transport within
the trans Golgi apparatus. Thus, BFA is known to affect
glycoprotein transport more profoundly in mammalian
cells than monensin.Virology Journal 2009, 6:147 http://www.virologyj.com/content/6/1/147
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Figure 1 (see legend on next page)
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Secretion of GP1 occurs in cells expressing high or low 
levels of LASV GPC
To assess if secretion of LASV glycoprotein is a phenome-
non resulting from high level expression of GPC, intracel-
lular and secreted GP1 levels driven by intron-A
containing or intronless CMV promoter constructs were
analyzed and quantitated. In HEK-293T/17 cells the aver-
age level of intracellular GP1 expression derived from
intronless CMV promoter constructs was 16% of that
obtained with intron-A counterparts (Figure 3A, lane 3).
Expression from the weaker CMV promoter resulted in
undetectable levels of secreted GP1, as assessed by western
blot analysis of cell culture supernatants (Figure 3B, lane
3). In an attempt to detect secreted GP1 from lower intra-
cellular GPC expression, LASV GP1-specific mAb L52-74-
7A was used to immunoprecipitate (IP) the glycoprotein
from cell culture supernatants. One millilitre of each
supernatant was subjected to IP with anti-GP1 mAb and
Protein G Sepharose, and the resulting immunoprecipi-
tates were detected by western blot. As shown in Figure 3C
the entire IP reaction (1) was resolved for control vector
(lane 1), intronless GPC (lane 3), and control GP1-TM
(lane 4) constructs. Conversely, a fraction (0.025) of each
of the intron-A driven GPC and sGP1 constructs were ana-
lyzed in the same blots for comparison (Figure 3C, lanes
2 and 5). The intracellular ratios of GP1 between intron-A
driven and intronless GPC constructs were calculated lin-
early based upon densitometry. Whereas intracellular
GP1 levels derived from expression of an intronless GPC
construct were, on average, 16% of those obtained with
the intron-A containing counterpart, the resulting secreted
GP1 was only 0.11%, or ~1/100 of the cellular ratio (Fig-
ure 3C, lane 3). A very minor GP1 band could be immu-
noprecipitated from the supernatants of GP1-TM
expressing cells (Figure 3C, lane 4). The GP1-TM construct
contains the LASV GP2 TM domain directly fused to the C-
terminus of the GP1 ORF, and the SKI-1/S1P protease
cleavage site, RRLL, remains intact. In this conformation
the vast majority of GP1-TM is not cleaved, and GP1 is
produced almost exclusively as a membrane-anchored
form. Expression of LASV glycoprotein constructs in
VERO cells generally produced similar results as those
obtained with HEK-293T/17 cells (Figure 3D), with the
notable exception of higher secreted levels of GP1 from
intronless CMV promoter-driven GPC (Figure 3D, lane 3).
Also, secreted levels of GP1 from a sGP1_RRAA-FLAG
construct were approximately twice those observed with
intron-A containing GPC (Figure 3D, lane 2 versus lane
5). In contrast, the same corresponding levels in HEK-
293T/17 cells were nearly matched (Figure 3A, C, lane 5).
To further assess the levels of secreted GP1 from VERO
cells expressing GPC under the control of an intronless
CMV promoter, supernatants were subjected with IP with
mAb L52-74-7A. Western blot analysis revealed that sig-
nificantly higher levels of sGP1 could be purified from the
supernatants of VERO cell expressed intronless GPC than
from HEK-293T/17 cells, as expected, based on analysis
on non-immunoprecipitated samples (data not shown).
GP1 remains associated with the cell membrane in LASV 
GPC expressing cells
Expression and localization of LASV GP1 in HEK-293T/17
cells was analyzed by immunofluorescence assay (IFA)
with mAb L52-74-7A on fixed and permeabilized, or live,
unfixed cells (Figure 4). All constructs used in LASV glyc-
oprotein expression for IFA were driven by intron-A con-
taining CMV promoters. Expression of GPC on fixed cells
was generally diffuse throughout the cytoplasm, with
bright distribution of the antigen throughout the periph-
eral outline of stained cells (Figure 4A, panels 1 and 3).
Expression of GPC on live cells, which were not permea-
ble to the antibody, and thus stained antigen present of
the outer leaflet of the membrane, showed primarily
bright punctate staining throughout the cellular periphery
Effect of metalloprotease inhibitors on the expression and secretion of GP1, and cytotoxicity on LASV GPC-expressing HEK- 293T/17 cells Figure 1 (see previous page)
Effect of metalloprotease inhibitors on the expression and secretion of GP1, and cytotoxicity on LASV GPC-
expressing HEK-293T/17 cells. Cells were transfected for 12 hours, followed by addition of metalloprotease inhibitors. (A) 
Supernatants were collected at 42 - 45 hours post transfection, cleared by centrifugation, and equal volumes from each reac-
tion were resolved on SDS-PAGE, blotted, and probed with anti-GP1 mAb L52-74-7A. (B) GP1 secretion was detected by 
western blot analysis as early as 12 hours post transfection, as shown in a longer exposure (lane 17B). Control pcDNA vector 
was also overexposed in the same blot (lane 18B). (C) Intracellular expression of GPC at the time of harvest (lane 13C), and 
the corresponding pcDNA vector control (lane 15C), were compared with the same conditions at 12 hours post transfection 
(lanes 17C, 18C). (D) Relative levels of secreted GP1 were determined from triplicate experiments by densitometry scanning 
of exposed x-ray films. Data was normalized against GPC+DMSO (= 1) and plotted as mean ± SD, N = 3. Data analysis using 
ANOVA did not reveal statistically significant differences between any of the conditions containing metalloprotease inhibitors 
and untreated GPC expressing controls (p > 0.05). (E) MTT cytotoxicity assay from triplicate experiments, plotted as mean 
A570 nm ± SD, N = 3. ANOVA established a statistically very significant difference (p < 0.001) between MMP-2 inhibitor I and 
the GPC+DMSO control only. The metalloprotease inhibitors and experimental designations outlined on the x-axis in E. apply 
to D., and correspond to the numeration in A., B, and C. Positions for secreted and intracellular GP1 (42 KDa), and unproc-
essed GPC (75 KDa) in cell extracts are noted.Virology Journal 2009, 6:147 http://www.virologyj.com/content/6/1/147
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Figure 2 (see legend on next page)
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(Figure 4B, panels 1 and 3). Unfixed, GPC-expressing cells
were extensively washed with staining buffer prior to incu-
bating with GP1-specific mAb to remove soluble GP1
from the reactions. Thus, staining with mAb L52-74-7A
on GPC-expressing unfixed cells detected GP1 associated
with the outer leaflet of the cell membrane. GP1-TM
expression on the cell surface was largely similar to that
observed with GPC on unfixed cells, with additional dif-
fuse stained throughout the cytoplasm (Figure 4C, panels
1 and 3). Soluble GP1 expression from sGP1-RRAA-FLAG
displayed diffuse intracellular staining, in addition to
bright antigen distribution throughout the periphery of
transfected cells (Figure 4D, panels 1 and 3). The LASV
GP1-specific mAb L52-74-7A did not stain empty vector
transfected cells (Figure 4D, panels 1 and 3). Cells were
counterstained with DAPI to enumerate nuclei (Figure 4A-
D, panels 2 and 3).
Secreted GP1 derived from expression of LASV GPC and 
sGP1 have disparate glycosylation patterns
The glycosylation profile of secreted GP1 was derived by
treatment of immunoprecipitated protein with PNGase-F,
Endo-H, or Neuraminidase, followed by western blot
analysis of protein migration on SDS-PAGE. The LASV
GP1 glycoprotein contains 7 predicted N-linked glyco-
sylation sites that could be accessible to removal by
PNGase-F. Secreted GP1 from GPC expression was fully
deglycosylated by PNGase-F, as determined by a loss of ca.
20 KDa from the mass of the protein detected on western
blots (Figure 5A, lane 2). The expected mass of LASV GP1
without carbohydrate moieties is 22771.82 Daltons
(ExPASy Compute pI/Mw tool [13-15]). Expression of
sGP1-RRAA-FLAG produced a secreted form of GP1 that
was largely deglycosylated by PNGase-F, with an addi-
tional moiety at ca. 24 KDa that could not be further
deglycosylated with higher levels of enzyme, additional
digestion time, or further denaturation (N = 4) (Figure 5B,
lane 2). Digestion of secreted GP1 from GPC expression
with Endo H produced a highly heterogeneous banding
pattern on western blots, with moieties ranging from the
fully glycosylated 42 KDa protein to approximately 25
KDa (N = 4) (Figure 5A, lane 3). Conversely, sGP1-RRAA-
FLAG was less susceptible to Endo H digestion, producing
mainly a heterogeneous banding pattern between 42 KDa
and 35 KDa, with an additional faint band at ca. 25 KDa
(N = 4) (Figure 5B, lane 3). Neither form of the secreted
GP1 protein resulted in mobility shifts upon digestion
with Neuraminidase (N = 3) (Figure 5A, B, lane 4). The
carbohydrate composition of both GP1 forms was further
dissected with a panel of lectin binding assays. Among the
five lectins employed, each with well characterized carbo-
hydrate binding specificities, only Galanthus nivalis agglu-
tinin (GNA) bound to LASV GP1, albeit differentially. The
lectin bound significantly stronger to GPC-derived sGP1
(Figure 5C, lane 1) than to sGP1-RRAA-FLAG (Figure 5C,
lane 3) (N = 3). The amount of glycoprotein loaded per
lane was assessed by densitometry analysis of GP1
detected on western blots with mAb L52-74-7A, and
determined to be nearly equal in every experiment (data
not shown). The internal kit control protein for GNA
binding, carboxyl peptidase Y (CpY), was run alongside
LASV GP1 and stained equivalently in both assays (Figure
5C, lanes 2 and 4).
Secreted GP1 from GPC and sGP1 expression have 
identical N-terminal sequences
Immunoprecipitated and PNGase-F deglycosylated GP1
protein from GPC and sGP1-RRAA-FLAG were subjected
to SDS-PAGE and transferred to PVDF membranes for N-
terminal sequence analysis by Edman degradation. The six
N-terminal amino acids from each protein were T-S-L-Y-
K-G, thus representing the SPase-cleaved form of the LASV
GP1 protein, as previously characterized [8].
Inhibition of GP1 secretion from HEK-293T/17 cells expressing LASV GPC by brefeldin A and monensin Figure 2 (see previous page)
Inhibition of GP1 secretion from HEK-293T/17 cells expressing LASV GPC by brefeldin A and monensin. (A) 
GPC expression in transfected cell extracts. GPC expression was analyzed at 12 (lane 1) and 36 hours (lane 2) post transfec-
tion in the absence of inhibitors. Intracellular GPC levels in BFA treated cells at the onset (lane 3), or 12 hours post transfec-
tion (lane 4), were compared to monensin treatment at the same time points (lanes 7 and 8, respectively). Vector controls, 
untreated (lane 5), treated with BFA (lane 6), or monensin (lane 9) only show detection of two endogenous cell proteins (end.). 
(B) GP1 secretion in corresponding culture supernatants. Significant levels of GP1 were detected only in supernatants of GPC 
transfected, untreated cells (lane 2), although a minor GP1 band was present in monensin treated cell supernatants at 12 hours 
post transfection (lane 8). (C) Relative levels of secreted glycoprotein in inhibitor treated conditions were compared to 
untreated GPC expressed sGP1 at 36 hours (= 1). BFA had a more pronounced effect on GPC and GP1 levels when added at 
the onset (p < 0.001) (lane 3) than at 12 hours post transfection (lane 4), and resulted in lower levels of expressed glycoprotein 
than under similar conditions with monensin (lanes 7 [p < 0.05] and 8, respectively). (D) MTT assay, plotted as mean ± SD, N 
= 3. ANOVA established statistically significant differences (p < 0.01 - 0.001) among several conditions when compared to 
untreated GPC and vector controls. Inhibitors and time of addition to reactions are outlined below D., and apply to all panels. 
Lane designations above A. apply to all panels.Virology Journal 2009, 6:147 http://www.virologyj.com/content/6/1/147
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Discussion
A panel of soluble MMP inhibitors with a wide range of
specificities was employed in the characterization of pro-
tease-mediated GP1 shedding from mammalian cells
expressing LASV GPC. A broad spectrum hydroxamic acid
inhibitor of MMPs, GM 6001 (inhibits MMP1, 2, 3, 8, 9),
metal ion chelators (EDTA, EGTA, 2,2 dipyridyl), a spe-
cific inhibitor of chymotrypsin-like serine proteases (α1-
antichymotrypsin), a cell surface aminopeptidase inhibi-
tor (Bestatin), an inhibitor of thermolysin-like protease
and metalloendopeptidases (Phosphoramidon), a broad
MMP inhibitor (phenanthroline), TNF-α convertase
(TACE) protease inhibitor-1 (TAPI-1), and specific inhib-
itors of MMPs (MMP2, 9), were added to growth medium
of LASV GPC-expressing mammalian cells in an attempt
to determine their role in the release of soluble GP1. None
of the inhibitors showed statistically significant inhibition
of GP1 shedding from HEK-293T/17 cells expressing
LASV GPC, although most compounds were tested at con-
centrations significantly greater than reported IC50 values
(Table 1). These results strongly suggest that GP1 is
released from cells as a soluble and uncoupled protein
Figure 3
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Intracellular expression and secretion of GP1 in cells trans- fected with intron-A containing and intronless LASV GPC  constructs Figure 3
Intracellular expression and secretion of GP1 in cells 
transfected with intron-A containing and intronless 
LASV GPC constructs. (A) Intracellular expression of 
glycoprotein constructs [C]. The 42 KDa GP1 protein was 
readily detected in intron-containing GPC (lane 2), GP1-TM 
(lane 4), and sGP1-RRAA-FLAG (lane 5) cell extracts. 
Expression of GPC from an intronless construct resulted in 
significantly lower levels of detectable GP1 (lane 3). In vector 
control (lane 1) only endogenous proteins ca. 47 and 55 KDa 
were detected (end.). Relative average expression levels of 
each glycoprotein compared to intron-A containing GPC are 
indicated below the respective lanes, as estimated by densit-
ometry. (B) Secreted GP1 was detected only in intron-A 
containing GPC and sGP1-RRAA-FLAG supernatants [S]. 
Relative level of secreted GP1 generated by sGP1-RRAA-
FLAG compared to GPC, as estimated by densitometry, is 
indicated below lane 5B. (C) Immunoprecipitation of GP1 
from GPC, GP1-TM, and sGP1-RRAA-FLAG transfected cell 
supernatants [IP]. Immunoprecipitated GP1 was detected in 
intron-A containing GPC (lane 2C) and sGP1-RRAA-FLAG 
(lane 5C), and at significantly lower levels in intronless GPC 
(lane 3C) expressing cell supernatants. A very faint GP1 band 
was detected in the immunoprecipitated GP1-TM sample 
(lane 4C). Vector control reactions did not show reactivity 
(lane 1C). Relative volume of each IP reaction loaded per 
lane is indicated above panel C. (D) Secreted GP1 profile in 
VERO cells transfected with LASV glycoprotein expression 
constructs. Average levels of GP1 from intronless GPC, 
GP1-TM, and sGP1-RRAA-FLAG, compared to those from 
intron-A containing GPC expression are shown below each 
lane in panels C and D (N = 4).Virology Journal 2009, 6:147 http://www.virologyj.com/content/6/1/147
Page 8 of 17
(page number not for citation purposes)
Expression profile of LASV GPC, GP1-TM, and sGP1-RRAA-FLAG in HEK-293T/17 cells by immunofluorescent microscopy Figure 4
Expression profile of LASV GPC, GP1-TM, and sGP1-RRAA-FLAG in HEK-293T/17 cells by immunofluores-
cent microscopy. HEK-293T/17 cells grown on cover slips and transfected with LASV glycoprotein constructs were stained 
with anti-GP1 mAb L52-74-7A and Alexa Fluor 488 secondary antibody, and counterstained with DAPI. Cells were fixed and 
permeabilized prior to staining (panels A, C, D, and E), or were stained live (panel B). Each panel shows captured fluorescent 
images of cells at 60× magnification, in oil immersion, with the same exposure settings used throughout for the given fluoro-
chrome (300 ms for FITC channel; 175 ms for DAPI channel). Cell surface and intracellular GP1 (Alexa Fluor 488, panels A - E), 
stained nuclei (DAPI, panels A - E), and merged images (merge, panels A - E) were captured with Slidebook 5.0 software (Intel-
ligent Imaging Innovations, Inc., Denver, CO). Images were not deconvolved or processed further. Each image is representative 
of at least 20 fields photographed and compared for each experimental condition.
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arising from the intracellular cleavage and processing of
the GPC complex. Further, it can be proposed that the 1:1
stoichiometry of GP1 and GP2 in cells expressing GPC
does not result in a 1:1 ratio of assembled tripartite com-
plex on the cell surface. It is possible that tripartite com-
plex assembly in the ER results in retention of a fraction of
GP2 in favour of GP1 secretion. This model is partly sup-
ported by our previous studies that established a critical
role for GP1 as a chaperone for correct processing and
secretion of GP2 [11]. These studies also suggested that
cell surface expression of GP2 without associated GP1 was
unlikely; GP2 expression resulted in very low levels of
intracellular protein, and it was undetectable on the cell
surface (unpublished data). Cytotoxicity of MMP inhibi-
tors was monitored by MTT uptake assays. MMP-2 inhib-
itor I resulted in significantly cytotoxicity compared to
untreated controls (p < 0.001, N = 3), but the resulting
release of GP1 from cells was not significantly affected
(Figure 1A, D, E, lane 8), indicating that de novo protein
synthesis and cellular secretory pathways were not tar-
geted by the inhibitor.
The mammalian expression system employed in these
studies was originally developed for high level production
of recombinant LASV proteins for diagnostic assay devel-
opment [11]. High level expression of soluble LASV GPC
resulted in both secretion of glycoprotein precursor
uncleaved by SKI-1/S1P, and high levels of sGP1.
Although CMV promoter strength has not been compared
to that of the LASV promoter, it is reasonable to suggest
that very high level expression of recombinant LASV genes
in mammalian cells could result in artefactual processing,
secretion, and stoichiometry of glycoprotein complex
components. It is evident that high level expression of sol-
uble GPC in HEK-293T/17 cells driven by CMV plus
intron-A overwhelms cellular SKI-1/S1P protease, as
approximately one half of the secreted glycoprotein is
uncleaved [11]. In order to address the possibility that
overexpression of GPC resulted in artefactual secretion of
GP1 we expressed the glycoprotein from an intronless
CMV-driven promoter. Expression of GPC from CMV-
intron-A driven vectors resulted in 8 - 10 fold higher levels
Figure 5
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Glycosylation profile of GPC and sGP1-RRAA-FLAG-derived  secreted GP1 assessed by digestion with endo- and exo-gly- cosidases, and by lectin binding profiles Figure 5
Glycosylation profile of GPC and sGP1-RRAA-FLAG-
derived secreted GP1 assessed by digestion with 
endo- and exo-glycosidases, and by lectin binding 
profiles. Immunoprecipitated secreted GP1 from LASV GPC 
expression (A) or sGP1-RRAA-FLAG expression (B) was 
subjected to digestion with PNGase F (lane 2), Endo H (lane 
3), or neuraminidase (lane 4). Untreated glycoprotein con-
trols were similarly processed, as outlined in methods, but 
enzymes were not added to reactions (lane 1). Proteins were 
subjected to SDS-PAGE and western blot analysis with bioti-
nylated anti-GP1 mAb L52-74-7A and SA-HRP. Molecular 
weights of fully glycosylated GP1 (42 KDa) and the com-
pletely deglycosylated form of the protein (22 KDa), are indi-
cated. (C) GNA lectin binding profile on immunoprecipitated 
GP1 from GPC expression (lane 1) or sGP1-RRAA-FLAG 
(lane 3). Control GNA binding for each reaction was per-
formed on CpY (lanes 2 and 4). The heavy chain of mAb L52-
74-7A reacted with GNA, and is indicated (mAb HC). 
Secreted GP1 from GPC expression reacted significantly 
stronger with GNA (lane 1) than with sGP1-RRAA-FLAG 
(lane 3). (D) Complete lectin panel binding profile on 
secreted GP1 from GPC or sGP1-RRAA-FLAG.Virology Journal 2009, 6:147 http://www.virologyj.com/content/6/1/147
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of cleaved intracellular GP1 than from intronless counter-
parts. Low levels of sGP1 in the supernatants of cells
expressing intronless GPC were detected only when the
glycoprotein was immunoprecipitated. An 8 - 10 fold
dilution of culture supernatant from cells expressing sGP1
still resulted in detection of significant levels of secreted
glycoprotein, whereas similar levels of immunoprecipi-
tated GP1 from intronless GPC expression required 400
fold higher volume of supernatant. These results suggest
that overexpression of GPC results in disproportionately
enhanced secretion of sGP1 when compared to lower
expression levels of the glycoprotein. Generally, expres-
sion and secretion levels of GP1 in the HEK-293T/17 line
paralleled those obtained with VERO cells, a common
line used for the propagation of Lassa virions and analysis
of LASV gene expression (Figure 3D).
Association of GP1 with the cell membrane as a compo-
nent of the tripartite glycoprotein complex was verified by
staining live cells overexpressing GPC. After extensive cell
washing to remove sGP1, followed by staining with a
LASV GP1-specific mAb, cell surface associated GP1 could
be readily detected. The staining pattern was less diffuse
than with fixed and permeabilized cells overexpressing
GPC, with bright fluorescence primarily associated with
the cell membrane. Thus, a fraction of the GP1 protein
associates with GP2 and SSP on the cell membrane of
GPC-transfected cells, whereas a soluble, un-associated
component is shed into the cellular milieu.
Sequencing of GP1 protein from expression of GPC or
sGP1 revealed identical N-termini through six amino
acids, suggesting that both forms of the glycoprotein
result from cleavage of pre-GPC by SPase at amino acid
58, and that the SSP functions as the secretory signal.
Protein deglycosylation and lectin binding studies
revealed significant heterogeneity in the carbohydrate
composition of the LASV GP1 protein. Whereas secreted
GP1 from expression of LASV GPC could be fully deglyc-
osylated with PNGase F (Figure 5A, lane 2), two distinct
forms could be observed in sGP1 from sGP1-RRAA-FLAG
expression. The 22 KDa band corresponding to a fully
deglycosylated sGP1 migrated just below a ca. 24 KDa
form of the protein, and it was consistently detected on
western blots (Figure 5B, lane 2). The average 14-residue
precursor of N-linked oligosaccharides adds approxi-
mately 2.6 KDa to the mass of a target protein ([GlnNAc
Table 1: Effects of matrix metalloprotease and secretory pathway inhibitors on GP1 shedding and cytotoxicty in HEK-293T/17 cells
inhibitor [] in assay Notes/references effect on GP1 shedding cytotox.(MTT) morphology (microscopy)
2,2 dipyridyl 1 μM Calbiochem - - enlarged cells
1,10 phenanthroline 10 μM ref. [12] - - detached cells
bestatin 10 μM1  -  1 0  μM working [] - - enlarged cells
α1-antichymotrypsin 4 μM ref. [12] - - normal
phosphoramidon 10 μMI C 50 = 4.6 μM - - enlarged cells
captopril 10 μM ref. [12] - - normal
MMP-9 inhibitor I 50 nM IC50 = 5 nM - - detached cells
MMP-2 inhibitor I 100 μMK i = 1.7 μM - + enlarged cells
GM6001 5 μMK i = 400 pM - 27 nM - - normal
TAPI-1 50 μMI C 50 = 100 nM - - normal
EDTA 5 mM 1 - 10 mM working [] - - rounded cells
EGTA 5 mM 1 - 10 mM working [] - - rounded cells
brefeldin A 15 μg/mL BD Golgi Plug™ +++ + rounded cells
monensin 10 μM BD Golgi Stop™ +++ + rounded cellsVirology Journal 2009, 6:147 http://www.virologyj.com/content/6/1/147
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× 3] + [Man × 9] + [Glc × 3]). Thus, the 24 KDa form of
sGP1-RRAA-FLAG that remains after digestion with
PNGase F suggests the presence of an oligosaccharide
branch other than N-linked in nature. Alternately, as
PNGase F is not able to cleave N-linked glycans from glyc-
oproteins when the innermost GlcNAc residue is linked to
an α1-3 Fucose residue [16], the possibility of this form of
linkage in sGP1-RRAA-FLAG exists. This type of modifica-
tion is most commonly found in plant and some insect
glycoproteins, however. Computational analysis of the
LASV GP1 protein sequence using OGPET v1.0 (Univer-
sity of Texas, El Paso [17] revealed the possibility of an O-
GalNAc (mucin type) glycosylation in GP1 at Ser 80
(SnISTnHL), with a predictive score of 0.599833 (cutoff =
0.4247). Additionally, NetGlycate 1.0 Server [18], a pre-
dictor of glycation of ε amino groups of lysines in mam-
malian glycoproteins, attributed a score of 0.914 to Lys5
in LASV GP1, which is significantly above the threshold of
0.5. Lectin-binding assays did not aid in resolving the gly-
cosylation pattern of the 24 KDa form of sGP1-RRAA-
FLAG. The lectins PNA (Peanut agglutinin) and DSA (Dat-
ura stramonium agglutinin), which recognize the core dis-
accharide galactose (1-3) N-acetylgalactosamine, and Gal-
(1-4)GlcNAc in complex and hybrid glycans, in O-gly-
cans, and GlnNAc in O-glycans, respectively, did not bind
to the 24 KDa sGP1 form. A higher degree of N-linked gly-
cosylation heterogeneity on LASV GP1 was obtained in
Endo H digestion profiles. Endo H removes only high
mannose and some hybrid types of N-linked carbohy-
drates from glycoproteins, and will not cleave more com-
plex glycan structures [19,20]. Soluble GP1 from GPC
expression revealed a more heterogeneous distribution of
high mannose and hybrid glycosylation than were present
in sGP1-RRAA-FLAG, indicating a higher content of man-
nose and/or hybrid structures. Conversely, it appears that
sGP1-RRAA-FLAG has a significantly higher content of
complex glycan structures, as determined by reduced
EndoH activity on the glycoprotein. These results were
confirmed by the differential staining of both GP1 forms
by GNA; soluble GP1 from GPC expression was heavily
stained with GNA, whereas sGP1-RRAA-FLAG showed sig-
nificantly dimmer reactivity. Densitometry analysis
showed a ratio of 2.27 ± 0.014 in GNA staining intensity
of GPC-derived GP1 versus sGP1-RRAA-FLAG (N = 3).
The marked differences in glycosylation of each form of
LASV GP1 could be attributed to a potentially different
translational and post-translational modification profile
and timeline in expressing cells. The process of transla-
tion, ER translocation, SPase and SKI-1/S1P cleavage, ER
retention of glycoproteins, and assembly of the LASV tri-
partite complex (GP1+GP2+SSP) has been somewhat dis-
sected, and constitutes a finely orchestrated process in the
ER and Golgi of mammalian cells. The correct processing
and assembly of the tripartite complex is essential for sub-
sequent binding of LASV virions via GP1 to the α-dystro-
glycan cellular receptor, and initiation of viral entry via
the fusion peptide on the N-terminus of GP2, a process
largely mediated by the presence of the intact SSP peptide.
Thus, it is conceivable that LASV GPC-derived glycopro-
teins remain accessible to ER resident glucosyltrans-
ferases, and the homologous lectins calnexin and
calreticulin longer than sGP1-RRAA-FLAG, resulting in an
overall different endpoint glycosylation pattern. Glucosyl-
transferases act as one of the primary protein folding qual-
ity control mechanisms in the ER, in concert with lectins,
peptidyl-propyl-isomerases, and chaperones that are
tightly regulated by nuclear transcription mediated by ER
membrane resident proteins (e.g. ATF6) that sense high
levels of protein misfolding in this organelle [21]. The for-
mation of hybrid and complex glycans takes place in the
medial and trans Golgi compartments. Therefore, proteins
residing in the ER which have not passed through the
Golgi cannot possess hybrid or complex N-linked struc-
tures. Thus, the intricate assembly process for the LASV
GPC complex would be expected to differ from that of sin-
gle glycoprotein expression from the sGP1-RRAA-FLAG
construct. The kinetics of GP1 secretion from expression
of GPC and sGP1-RRAA-FLAG do not differ significantly,
as the onset for detection of each form of the glycoprotein
in the extracellular medium occurs at approximately 12
hours post transfection (with CMV+intronA driven con-
structs). Post-translational processing and secretion of
sGP1-RRAA-FLAG is not necessarily faster than GPC
expressed GP1, but it is executed differently. It is notewor-
thy to point that such findings contrast with previously
reported results by our group that showed clear and com-
plete removal of high mannose glycans from sGP1 and
sGP2 generated with the same expression constructs and
cell type [11]. Such contrasting results point to subtle dif-
ferences in culture conditions that could significantly
affect resulting glycosylation patterns. Although the HEK-
293T/17 clone used in both studies was obtained from the
same source (American Type Culture Collection [ATCC]),
the studies were performed with different lots of culture
media and supplements, namely fetal bovine serum. It
has been extensively reported that subtle differences in
cell culture environments, including changes in medium
composition can result in significant differences in glyco-
sylation patterns of secreted glycoproteins. Such impact
on glycosylation is a primary focus of product quality con-
trol in many glycoprotein-based biopharmaceutical prod-
ucts, such as therapeutic antibodies, erythropoietin, and
reproductive hormones [22-26]. Lastly, treatment of
secreted GP1 from GPC and sGP1-RRAA-FLAG expression
did not result in observable shifts with neuraminidase.
Neuraminidase (Acetyl-neuraminyl hydrolase; Sialidase)
catalyzes the hydrolysis of α2-3, α2-6, and α2-8 linked N-
acetyl-neuraminic acid residues from glycoproteins and
oligosaccharides [27,28]. These results were further con-
firmed by the lack of binding to both forms of GP1 by theVirology Journal 2009, 6:147 http://www.virologyj.com/content/6/1/147
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lectins MAA (Maackia amurensis agglutinin) and SNA
(Sambucus nigra agglutinin), which are specific for α2-3
and  α2-6 galactose, respectively. Thus, it appears that
LASV GP1 is not synthesized with terminal sialic acid res-
idues in its carbohydrate profile, irrespective of the glyco-
protein precursor.
It is well known that hydrophobic interactions predomi-
nate over the proper and improper folding of proteins.
Further, the hydrophobic areas of high mannose N-gly-
cans are closely associated with promotive effects on pro-
tein folding, possibly depressing the hydrophobic
interactions unfavorable to the proper folding of nascent
polypeptides in the E.R. It has been established by Jitsu-
hara et al. [29], Narhi et al. [30], and others that higher
oligomannose chains of glycosylated proteins promote
protein folding more strongly than lower ones [31]. Of
noteworthy mention is the folding of influenza virus
hemagglutinin with a truncated N-glycan
Glc1Man5GlcNAc2 moiety that normally interacts with the
lectin calnexin in the E.R. is markedly depressed [32]. The
E.R. resident lectins calnexin and calreticulin tether
monoglucosylated high mannose N-glycans from nascent
proteins, resulting in suppression of aggregation, thus
promoting protein folding [33]. Many studies have estab-
lished the correlation between proper protein glycosyla-
tion with the acquisition and retention of glycoprotein
biological activities. It is reasonable to expect that in the
arenaviral tripartite complex the proper folding of the
individual glycoprotein subunits, and the interaction with
the SSP, have critical roles in establishing functional bind-
ing of virions to host cell receptors and subsequent fusion
and viral entry. Our own previous LASV GP1 protein
expression studies in multiple biological systems have
resulted in markedly different results. Although expres-
sion of full length GP1 in E. coli was achievable, the lack
of glycosylation in the prokaryotic system required the
presence of sodium dodecyl sulfate (SDS), reducing
agents (e.g. dithiothreitol [DTT]), and the zwitterion mor-
pholino-ethanesulfonic acid (MES) in the purification
scheme in order to yield non-aggregated protein [34]. Fur-
ther processing of bacterial expressed GP1 protein for ana-
lytical assays that required removal of SDS and DTT
readily resulted in aggregation. In contrast, expression of
multiple forms of LASV GP1 in mammalian cells always
resulted in glycosylated, soluble protein, although aggre-
gation of the standalone glycoprotein remained an issue
[11]. Further characterization of post-translational
processing of the arenaviral glycoprotein complex may be
of crucial importance in the establishment of viral infec-
tivity correlates, as well as pave the way for identification
of disease susceptibility markers, and development of
effective vaccines and therapeutics.
The present studies affirm the transition of GP1 from the
ER to the Golgi in its path toward secretion, and that the
secretory component of GPC follows the same route.
Complete or nearly complete inhibition of GP1 secretion
in supernatants of cells transfected with GPC and treated
with BFA and monensin is indicative of a secretory path-
way mediated phenomenon. This conclusion is further
strengthened by the lack of inhibition of GP1 secretion
from GPC-expressing cells treated with a wide range of
MMP inhibitors. Despite secretion of GP1 from GPC-
expressing cells, a surface membrane-associated GP1 com-
ponent was specifically visualized on live cells. These
observations are indicative of a secreted GP1 component,
in addition to the presence of a cell surface expressed,
functional tripartite glycoprotein complex. A proposed
model outlining the secretory pathway of LASV GP1 is
graphically displayed in Figure 6.
Together, these data strongly suggest dual modalities in
LASV GPC expression; the formation of a fully functional
tripartite complex for display on the surface of infectious
virions, and the secretion of a soluble GP1 component
with as of yet uncharacterized function. The fate of un-
associated GP2 during expression of LASV GPC was not
investigated in these studies, but it warrants analysis, as
the stoichiometry of the glycoprotein complex depends
on the ratio of the available individual components. Dol-
nik et al. [12] have partly characterized the role of a solu-
ble GP component in EBOV, and have proposed a role in
the infectivity of the virus in vivo. According to Dolnik et
al., the secreted EBOV GP component acts as an immune
decoy, by targeting the humoral immune system and pos-
sibly removing from circulation antibodies with innate
neutralizing activity against the virus. This mechanism
would provide circulating infectious virions a clearer path
toward infection of new target cells, with enhanced viru-
lence. Also, Wahl-Jensen et al. have further delineated the
role of secreted EBOV GP in activation of primary target
cells [35,36]. These studies revealed that rigid presenta-
tion of the EBOV glycoprotein, as it's displayed on the sur-
face of virions is critical for activation of pro-
inflammatory cytokines and chemokines, whereas soluble
glycoprotein failed to elicit any response. Additionally,
EBOV GP(1,2) in viral particle-associated form mediated
endothelial cell activation and decreased cell barrier func-
tion, whereas sGP, the major soluble glycoprotein of
EBOV, demonstrated an anti-inflammatory role by pro-
tecting the endothelial cell barrier function.
Although a similar mechanism has not been ascribed to
arenaviruses, our work presents a platform upon which to
investigate this phenomenon in vivo. The secreted GP1
component resulting from GPC expression has not been
detected in the serum of LASV infected patients, and fur-
ther work will be performed by our group in an attempt toVirology Journal 2009, 6:147 http://www.virologyj.com/content/6/1/147
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test the feasibility of this hypothesis. If the phenomenon
of GP1 shedding is present in vivo the glycoprotein should
be preferentially detected in the early stages of arenaviral
infection, when circulating antigens are present at the
highest levels. Soluble GP1 in serum could be separated
from virions by selective size filtration, thus providing a
simple and easily deployable platform for identification
of the soluble glycoprotein component. If confirmed, are-
naviral glycoprotein shedding could result in the develop-
ment of more sensitive and earlier detection diagnostics,
as well as establish new correlates of pathogenesis and
immune evasion by this class of hemorrhagic fever
viruses.
Conclusion
The shedding of GP1 from cells expressing GPC results
from secretion of a cleaved and un-associated fraction of
the protein. This phenomenon is not the result of cleavage
of GP1 from the tripartite complex expressed on the cell
surface, and it is not mediated by cellular MMPs. Instead,
secretion of GP1 occurs when GPC is processed into GP1
and GP2 in the ER, and a significant fraction of this pro-
tein is shuttled through the secretory pathway and is
released into the extracellular medium. Both forms of
secreted GP1 share N-terminal sequences, but have dis-
similar glycosylation profiles that suggest a differential
Schematic representation of arenaviral glycoprotein expression pathway and secretory forms Figure 6
Schematic representation of arenaviral glycoprotein expression pathway and secretory forms. Arenaviral glyco-
protein (GP) mRNA is transcribed from plasmid DNA in the host cell (1), and is directed to the rough endoplasmic reticulum 
(RER) for translation by associated ribosomes. The nascent polyprotein is directed to the RER lumen by the unique arenaviral 
SP, where SPases cleave the SP from the GP polyprotein precursor (2). In the RER the GP precursor is cleaved by SKI-1/S1P to 
yield GP1 and GP2 subunits (3). Wild type GP is possibly comprised of covalently linked, or non-covalently associated GP1 and 
GP2 subunits, and associated SP (3). Glycosylation of GP1 and GP2 is mediated by glycosyltransferases in the RER or in the 
Golgi cisternae (4). Membrane bound vesicles transport proteins to the cis face of the Golgi where final processing and assem-
bly of the GP complex occurs. Fully assembled and glycosylated GP complex or subunits are packaged in exocytic vesicles 
which emerge from the trans face of the Golgi and are directed toward the plasma membrane. Glycoprotein complex is 
anchored to the cell membrane via the transmembrane domain of GP2 (5a). A complexed heterodimeric GP1-GP2 is displayed 
in 5a. Extracellular GP1 originating from GPC expression is a secreted glycoprotein isoform (5b). The positions of BFA and 
monensin inhibitory action along the secretory pathway are indicated. The role of LASV GP2 in the secretory pathway of GP1 
was not elucidated in these studies (black box). A graphic representation of each relevant component in the outlined pathway 
is shown in the legend box.Virology Journal 2009, 6:147 http://www.virologyj.com/content/6/1/147
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retention and glycoprotein processing timeline in the ER
and Golgi compartments.
Methods
Cells, plasmids, antibodies
HEK-293T/17 cells (ATCC CRL11268) were maintained
in complete high glucose Dulbecco's Modified Eagle
Medium (cDMEM) supplemented with non-essential
amino acids (NEAA) and 10% heat-inactivated fetal
bovine serum (ΔFBS).
Vero cells (ATCC CRL 1587) were maintained in cDMEM
supplemented with NEAA and 5% ΔFBS. Plasmid con-
structs expressing LASV GPC, GP1-TM, and sGP1, and the
backbone vector pcDNA3.1+zeo:intA were described else-
where [11]. For immunoassays, Dr. Randal Schoepp
kindly provided the LASV-specific GP1 mAb L52-74-7A,
which was generated against purified gamma-irradiated
LASV, as previously described [37]. Horseradish peroxi-
dase (HRP)-conjugated secondary antibodies specific for
mouse IgG were purchased from Kirkegaard and Perry
Laboratories (KPL, Gaithersburg, MD). Alexa Fluor 488-
conjugated goat F(ab')2 anti-mouse IgG secondary anti-
bodies for immunofluorescence assays were purchased
from Molecular Probes. Anti-LASV GP1 mAb L52-74-7A
was biotinylated with EZ-Link® NHS-Biotin (Pierce, Rock-
ford, IL), and desalted with Zeba™ Desalt Spin Columns
(Thermo Scientific, Rockford, IL), according to manufac-
turer's instructions.
Transient expression of LASV gene constructs
Recombinant LASV protein expression was analyzed in
HEK-293T/17 or VERO cells transiently transfected with
mammalian expression vector DNAs, which were pre-
pared using the PureLink HiPure plasmid filter midiprep
kit (Invitrogen, Carlsbad, CA). The negative control vector
pcDNA3.1(+):intA was included in all transfections.
Briefly, 1 × 106 cells were seeded per well of a Poly-D-
Lysine-coated 6-well plate in 2 mL of cDMEM. After over-
night incubation in growth conditions cells were trans-
fected with unrestricted recombinant plasmid DNAs using
Lipofectamine™ 2000 (Invitrogen), according to the man-
ufacturer's instructions. Four μg of each plasmid DNA
were used per transfection. Transfections were incubated
for the times described in results, at 37°C, 5% CO2, 90%
RH, after which cell culture supernatants were collected
and clarified by centrifugation. To prepare cell extracts
from transfected cultures, cell monolayers were carefully
washed twice with Ca++- and Mg++-free PBS, pH7.4, col-
lected by gentle dislodging, transferred to 1.5 mL polypro-
pylene tubes, and lysed for 10 minutes in a mammalian
cell lysis buffer comprised of 50 mM Tris buffer, pH 7.5, 1
mM EDTA, 0.1% SDS, 0.5% deoxycholic acid, 1% Igepal
CA-360, and a protease inhibitor cocktail (Sigma Aldrich,
St. Louis, MO), according to the manufacturer's instruc-
tions. The insoluble fraction was pelleted by centrifuga-
tion at 14,000 × g for 10 minutes, and the supernatants
were transferred to fresh tubes. Protein concentration was
determined for each sample by A280 with A260 subtrac-
tion, and verified using a Micro BCA™ Protein Assay Kit, as
outlined by the manufacturer (Thermo Scientific).
Metalloprotease and secretory pathway inhibition assays
Metalloprotease inhibitors were purchased from Sigma
(1,10-Phenanthroline monohydrate, 2,2'-Dipyridyl Rea-
gentPlus®, Bestatin hydrochloride, Phosphoramidon diso-
dium salt, α1-Antichymotrypsin, EDTA, EGTA) or
Calbiochem (MMP-2 Inhibitor I, MMP-9 Inhibitor I,
InSolution™ GM 6001, InSolution™ TAPI-1, Captopril),
and resuspended in 100% DMSO (Sigma), or with cell
culture medium when appropriate, at 100× concentra-
tion. Inhibitors were diluted in growth medium for anal-
ysis, at a final DMSO concentration of 1%. For inhibition
assays HEK-293T/17 cells were transiently transfected
with plasmid DNAs in 6-well plates, as described above,
for 12 hours prior to the addition of metalloprotease
inhibitors. Transfection medium was then removed and
cells were washed twice with 1× PBS, pH7.4, followed by
addition of 2 mL of fresh growth medium containing
inhibitors. Plates were returned to the growth chamber
and reactions were harvested between 42 - 45 hours post
transfection by collecting supernatants and generating
whole cell protein extracts, as described above. The Golgi
secretory pathway inhibitors brefeldin A and monensin
were purchased from Sigma, and diluted in growth
medium to 15 μg/mL and 10 μM, respectively. Inhibitors
were added to cells at the time of transfection with
pcDNA3.1(+):intA or pcDNA3.1(+):intA:LASV GPC, or at
12 hours. Supernatants and cell extracts were harvested at
36 hours post transfection for western blot analysis.
Western blot and densitometry analyses
Expression of LASV GP1 in cell extracts and culture super-
natants was confirmed by Western blot analysis using
anti-LASV GP1 mAb L52-74-7A and a horseradish peroxi-
dase (HRP)-conjugated goat anti-mouse IgG (H+L) sec-
ondary antibody. Briefly, 10 μg of total cell protein in 10
μL (~1 × 105 cell equivalents), or 26 μL of cell culture
supernatant were resolved on 10% NuPAGE Novex Bis-
Tris gels, according to the manufacturer's specifications
(Novex, San Diego, CA). All samples in these studies were
denatured and reduced in SDS-PAGE buffer containing
DTT. Proteins were transferred to 0.45-μm nitrocellulose
membranes, blocked, and probed in 1× PBS, pH 7.4, 5%
non-fat dry milk, 0.05% Tween-20, and 0.1% thymerosal.
Membranes were then incubated in LumiGlo chemilumi-
nescent substrate (KPL) and exposed to Kodak BioMax MS
Film. Developed films were subjected to high resolution
scanning for densitometry analysis. Quantification of
band intensity was performed using National Institutes ofVirology Journal 2009, 6:147 http://www.virologyj.com/content/6/1/147
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Health ImageJ 1.41o software http://rsb.info.nih.gov/ij,
and following the procedure outlined in http://www.luke
miller.org/journal/2007/08/quantifying-western-blots-
without.html, using TIFF files.
Immunoprecipitation
Soluble GP1 was immunoprecipitated from 1 mL of trans-
fected culture supernatants with 2 μg of anti-LASV GP1
mAb L52-74-7A and Protein G-Sepharose® 4B Fast Flow,
using a Protein G Immunoprecipitation Kit (Sigma),
according to the manufacturer's instructions. Immuno-
precipitated proteins were denatured and reduced, sepa-
rated by SDS-PAGE, and blotted as outlined above. GP1
was detected with biotinylated anti-LASV GP1 mAb L52-
74-7A and ImmunoPure® Streptavidin-HRP (Thermo Sci-
entific).
Cell proliferation assay
HEK-293T/17 cell cytotoxicity induced by metallopro-
tease inhibitors was monitored with a TACS™ MTT Cell
Proliferation Assay (R&D Systems, Minneapolis, MN),
according to manufacturer's instructions. The transfection
procedure outlined above for 6-well plates was scaled
down to a 96-well format, with each condition analyzed
in triplicate. Data was plotted as mean absorbance at 570
nm, with standard deviation, and background correction
at 650 nm.
Immunofluorescence assay
HEK-293T/17 cells were seeded on Poly-D-Lysine-coated
sterile glass cover slips (BD Biosciences, Walkersville, MD)
in 24-well plates. Cells were transfected as outlined above.
At 72 hours post-transfection cells were washed with cold
HBSS and were either fixed in 2% methanol-free formal-
dehyde, or incubated in 1× PBS, pH 7.4/1% heat inacti-
vated FBS/0.1% NaN3 for live cell staining. Fixed cells
were incubated for 20 minutes in 50 mM NH4Cl to reduce
background fluorescence, followed by permeabilization
with 0.1% Triton-X 100 for 5 minutes, and blocking with
8% heat inactivated goat serum for one hour. Cells were
stained with anti-LASV GP1 mAb L52-74-7A diluted to 2
μg/mL in 0.8% goat serum/0.1% Triton-X 100, for one
hour. After washing, cells were incubated with Alexa Fluor
488 Goat F(ab')2 anti-mouse IgG (Molecular Probes/Inv-
itrogen) diluted to 1 μg/mL in staining buffer containing
1 μM DAPI (Invitrogen), for 1 hour. Cover slips were
mounted on ethanol washed glass slides with ProLong®
antifade reagent (Invitrogen). Reactions were cured for 48
hours prior to microscopy. Live cells were stained with the
same primary, secondary antibodies and DAPI, for one
hour each in 1× PBS, pH 7.4/1% heat inactivated FBS/
0.1% NaN3, followed by mounting and curing, as
described above. All reactions were performed at room
temperature, and were washed three times with 1× DPBS
between steps. Stained cells were imaged with a Zeiss Axi-
oplan 2 fluorescent microscope equipped with an Intelli-
gent Imaging Innovations CCD (Denver, CO), using a
Plan-APOCHROMAT 63X/1,4 oil DIC objective.
PNGase F, Endo H, and Neuraminidase assays
The glycosylation patterns in secreted GP1 generated from
expression of LASV GPC and sGP1 were resolved by treat-
ment with the glycosidases PNGase F, Endo H, and Neu-
raminidase. Immunoprecipitated GP1 from transiently
transfected HEK-293T/17 cell supernatants were subjected
to treatment with 500 NEB U of PNGase F, Endo H, or
Neuraminidase for 1 hour using the reaction conditions
suggested by the manufacturer (New England Biolabs).
Control reactions were similarly processed except that
enzymes were not added. Following incubation proteins
were resolved by reducing SDS-PAGE, blotted, probed
with biotinylated anti-LASV GP1 mAb L52-74-7A and
Streptavidin-HRP, and developed as described above.
Lectin-based Glycan differentiation assays
Glycosylation patterns on secreted GP1 were further char-
acterized via binding of glycan-specific lectins using a DIG
Glycan Differentiation Kit (Roche Applied Science, Man-
nheim, Germany), according to the manufacturer's
instructions. Immunoprecipitated GP1 from expression
of LASV GPC and sGP1 was resolved on SDS-PAGE, blot-
ted onto nitrocellulose, and subjected to lectin binding
assays.
N-terminal protein sequencing
Immunoprecipitated GP1 protein was resolved by SDS-
PAGE, blotted onto PVDF membranes, stained with Pon-
ceau Blue and destained in water. N-terminal sequence
determination of the 42 KDa protein was performed by
Edman degradation and carried out in an Applied Biosys-
tems Model 4949 CLC protein suquenator. Phenylthiohy-
dantoin derivatives of amino acids were analyzed on-line
with an Applied Biosystems Model 785A/140C/610A ana-
lyzer. All reagents and solvents were from Applied Biosys-
tems.
Statistical analyses
Statistical analysis of data was performed with GraphPad
InStat, V3.06 (GraphPad Software, Inc., San Diego, CA),
using Analysis of Variance (ANOVA).
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